Activating Soluble Guanylate Cyclase for Non-Proliferative Diabetic Retinopathy (NPDR) Treatment
Time: 2:30 pm
day: Day One
Details:
- Presenting preclinical data on runcaciguat’s ability to activate soluble guanylate cyclase, aiming to improve retinal blood flow and reduce inflammation in NPDR
- Designing the Phase 2 NEON-NPDR trial to demonstrate how runcaciguat’s preclinical efficacy translates into clinical benefits for patients with NPDR
- Reflecting on current trial results that indicate potential improvements in retinal health and a reduced risk of vision-threatening complications
